Updated PRESERVE-003 data strengthened the survival signal against docetaxel, but pivotal confirmation remains pending
Key Takeaways
- Gotistobart achieved median overall survival of 18.5 months versus 10.0 months with docetaxel.
- The hazard ratio for death was 0.56, with a nominal p-value of 0.0295.
- The result came from an 87-patient, non-pivotal stage; the pivotal portion remains underway.
Data Snapshot
| Metric | Gotistobart | Docetaxel |
|---|---|---|
| Patients | 45 | 42 |
| Treatment | Two 10 mg/kg loading doses, then 6 mg/kg every three weeks | 75 mg/m² every three weeks |
| Median overall survival | 18.5 months | 10.0 months |
| OS hazard ratio vs docetaxel | 0.56 | Reference |
| Nominal p-value | 0.0295 | — |
| Grade ≥3 treatment-related adverse events | 44.4% | 48.8% |
What Happened
BioNTech and OncoC4 reported updated survival data from stage 1 of PRESERVE-003, a randomized Phase 3 trial comparing gotistobart with docetaxel in metastatic squamous non-small cell lung cancer after prior immunotherapy and chemotherapy.
At the July 17, 2026 data cutoff, 87 patients had been followed for a median of 25.4 months. Median overall survival reached 18.5 months with gotistobart and 10.0 months with docetaxel. The hazard ratio was 0.56, with a nominal p-value of 0.0295.
Grade 3 or higher treatment-related adverse events occurred in 44.4% of patients receiving gotistobart and 48.8% of those receiving docetaxel. (BioNTech PRESERVE-003 update)
The updated result was presented at the 2026 World Conference on Lung Cancer. (Reuters coverage)
Why It Matters
Docetaxel remains a common later-line option for squamous NSCLC after progression on platinum chemotherapy and PD-1 or PD-L1 inhibition. Gotistobart is attempting to replace that chemotherapy step with a differentiated form of CTLA-4 immunotherapy.
Gotistobart is a pH-sensitive antibody designed to release CTLA-4 after the antibody–receptor complex enters an acidic endosome. This allows CTLA-4 to recycle to the cell surface rather than being directed toward lysosomal degradation.
The proposed result is preservation of peripheral CTLA-4 checkpoint activity while maintaining surface CTLA-4 on tumor-infiltrating regulatory T cells, or Tregs. These CTLA-4-high Tregs may remain available for Fc-dependent depletion within the tumor microenvironment. This selectivity remains a mechanistic hypothesis that requires further clinical confirmation. (Nature Medicine study)
Want a closer look at the biology? Read my BP Science analysis: How Gotistobart Preserves CTLA-4 Recycling.
BP View
The updated analysis strengthens the earlier survival signal because median overall survival can now be estimated in both groups. An 8.5-month difference against docetaxel is clinically notable in a population with limited later-line options.
The hazard ratio changed from 0.46 in the earlier analysis to 0.56 with longer follow-up. This does not invalidate the result, but it shows that the estimated magnitude of benefit changed as the dataset matured.
The central limitation is that these results came from the 87-patient, non-pivotal stage 1 portion of PRESERVE-003. The ongoing pivotal stage 2 portion will determine whether the survival advantage is reproducible in a larger squamous NSCLC population.
Safety also requires more than a comparison of headline event rates. Immune-mediated toxicity from CTLA-4 inhibition differs from chemotherapy-associated toxicity, so similar Grade 3 or higher event rates do not establish equivalent tolerability. Gotistobart has produced an encouraging survival signal, but its clinical position still depends on pivotal confirmation.
Gotistobart has moved the survival signal forward, but the pivotal stage remains the final checkpoint.
Related Post
For another recent development in biomarker-defined lung cancer, read my analysis: GSK Plans First-Line Jideytro Filing After 94% Response Rate.
About BP
Biopharma Perspective provides independent analysis of biopharma news, clinical data and drug mechanisms. Each article connects the headline result with the science, competitive context and unanswered questions that could shape future development.
Leave a Reply